S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Stock Caught Trading Under Secret Name (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
PROOF: New One Ticker (Weekly) Payouts (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
PROOF: New One Ticker (Weekly) Payouts (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Stock Caught Trading Under Secret Name (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
PROOF: New One Ticker (Weekly) Payouts (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
PROOF: New One Ticker (Weekly) Payouts (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Stock Caught Trading Under Secret Name (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
PROOF: New One Ticker (Weekly) Payouts (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
PROOF: New One Ticker (Weekly) Payouts (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
AI Stock Caught Trading Under Secret Name (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
PROOF: New One Ticker (Weekly) Payouts (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
PROOF: New One Ticker (Weekly) Payouts (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
NASDAQ:GNPX

Genprex (GNPX) Stock Price, News & Analysis

$4.29
-0.11 (-2.50%)
(As of 02/20/2024 ET)
Today's Range
$4.01
$4.38
50-Day Range
$4.29
$11.21
52-Week Range
$4.01
$74.80
Volume
25,524 shs
Average Volume
88,693 shs
Market Capitalization
$6.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Genprex MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($19.60) to ($14.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars


GNPX stock logo

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

GNPX Stock News Headlines

Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Genprex Provides Business Update and Outlook for 2024
Genprex to Present at BIO-Europe 2023
Genprex to Present at BIO-Europe 2023 Conference
Genprex Schedules, Hosts Virtual Key Opinion Leader Event
Genprex to Present at Upcoming H.C. Wainwright Conference
See More Headlines
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2019
Today
2/20/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-23,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$18.55 per share

Miscellaneous

Free Float
1,315,000
Market Cap
$6.39 million
Optionable
Optionable
Beta
-0.47
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John Rodney Varner (Age 67)
    Co-Founder, Chairman, President & CEO
    Comp: $886.97k
  • Mr. Ryan M. Confer M.S. (Age 42)
    Chief Financial Officer
    Comp: $606.57k
  • Ms. Catherine M. Vaczy Esq. (Age 63)
    Executive VP, General Counsel, Corporate Secretary & Chief Strategy Officer
    Comp: $704.93k
  • Mr. David M. Schloss
    Senior Vice President of Human Resources
  • Mr. Thomas C. Gallagher Esq.
    Senior Vice President of Intellectual Property & Licensing
  • Dr. Mark S. Berger M.D. (Age 69)
    Chief Medical Officer
  • Dr. Suzanne Thornton-Jones
    Senior Vice President of Regulatory Affairs & Quality
  • Dr. Jack A. Roth F.A.C.S.
    M.D., Chairman of Scientific & Medical Advisory Board














GNPX Stock Analysis - Frequently Asked Questions

How have GNPX shares performed in 2024?

Genprex's stock was trading at $9.20 at the beginning of 2024. Since then, GNPX stock has decreased by 53.4% and is now trading at $4.29.
View the best growth stocks for 2024 here
.

Are investors shorting Genprex?

Genprex saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 53,900 shares, an increase of 38.6% from the January 15th total of 38,900 shares. Based on an average daily volume of 47,200 shares, the short-interest ratio is presently 1.1 days. Currently, 3.7% of the company's stock are sold short.
View Genprex's Short Interest
.

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our GNPX earnings forecast
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its earnings results on Monday, April, 1st. The company reported ($9.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.40) by $3.80.

When did Genprex's stock split?

Genprex shares reverse split before market open on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), Advanced Micro Devices (AMD).

Who are Genprex's major shareholders?

Genprex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner.
View institutional ownership trends
.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 2/21/2024 by MarketBeat.com Staff